Epicatechin influences primary hemostasis, coagulation and fibrinolysis.
The different stages of hemostasis (i.e., primary hemostasis, coagulation and fibrinolysis) are involved in the early atherothrombosis steps. This study aimed to investigate the effect of epicatechin, one major flavonoids compound, on the hemostasic phenotype using in vitro global assays clinically relevant because mimicking the complex in vivo systems. Plasma samples from 10 healthy volunteers were spiked with increasing concentrations of epicatechin (1 to 100 µM). Epicatechin effect on primary hemostasis, coagulation and fibrinolysis was assessed by measuring platelet aggregation using light transmission aggregometry, thrombin generation and clot lysis time (CLT), respectively. Epicatechin (100 µM) significantly decreased the maximal platelet aggregation induced by adenosine diphosphate (-39%), thrombin receptor activating peptide (-48%), epinephrine (-30%) and collagen (-30%). The endogenous thrombin potential was significantly reduced starting from 1 µM epicatechin (1332 ± 230 versus 1548 ± 241 nM.min for control) (p<0.01). Fibrinolysis was promoted by epicatechin, as indicated by CLT decrease by 16 and 33% with 10 and 100 µM epicatechin respectively, compared with control (1271 ± 775 sec). Epicatechin reduces platelet function and lead to an anticoagulant and pro-fibrinolytic profile. These findings provide new evidence for the interest of epicatechin for cardiovascular disease prevention.